NVS
Price
$129.73
Change
+$1.31 (+1.02%)
Updated
Sep 5 closing price
Capitalization
249.99B
50 days until earnings call
NVSEF
Price
$130.25
Change
-$0.47 (-0.36%)
Updated
Sep 3 closing price
Capitalization
249.99B
Interact to see
Advertisement

NVS vs NVSEF

Header iconNVS vs NVSEF Comparison
Open Charts NVS vs NVSEFBanner chart's image
Novartis AG
Price$129.73
Change+$1.31 (+1.02%)
Volume$1.34M
Capitalization249.99B
Novartis AG
Price$130.25
Change-$0.47 (-0.36%)
Volume$242
Capitalization249.99B
NVS vs NVSEF Comparison Chart in %
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. NVSEF commentary
Sep 08, 2025

To understand the difference between Novartis AG - ADR (NVS) vs. Novartis AG - Ordinary Shares (Registered) (NVSEF) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (NVS: $129.73 vs. NVSEF: $130.25)
Brand notoriety: NVS and NVSEF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 84% vs. NVSEF: 2%
Market capitalization -- NVS: $249.99B vs. NVSEF: $249.99B
NVS [@Pharmaceuticals: Major] is valued at $249.99B. NVSEF’s [@Pharmaceuticals: Major] market capitalization is $249.99B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileNVSEF’s FA Score has 3 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • NVSEF’s FA Score: 3 green, 2 red.
According to our system of comparison, both NVS and NVSEF are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 6 TA indicator(s) are bullish while NVSEF’s TA Score has 6 bullish TA indicator(s).

  • NVS’s TA Score: 6 bullish, 3 bearish.
  • NVSEF’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both NVS and NVSEF are a good buy in the short-term.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +2.51% price change this week, while NVSEF (@Pharmaceuticals: Major) price change was -0.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.16%. For the same industry, the average monthly price growth was +3.97%, and the average quarterly price growth was +10.41%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($250B) and NVSEF($250B) have the same market capitalization . NVSEF (18.99) and NVS (18.91) have similar P/E ratio . NVS YTD gains are higher at: 38.116 vs. NVSEF (35.536). NVS (22.7B) and NVSEF (22.7B) have comparable annual earnings (EBITDA) . NVS (7B) and NVSEF (7B) have equal amount of cash in the bank . NVS (32.6B) and NVSEF (32.6B) have identical debt. NVS (55.2B) and NVSEF (55.2B) have equivalent revenues.
NVSNVSEFNVS / NVSEF
Capitalization250B250B100%
EBITDA22.7B22.7B100%
Gain YTD38.11635.536107%
P/E Ratio18.9118.99100%
Revenue55.2B55.2B100%
Total Cash7B7B100%
Total Debt32.6B32.6B100%
FUNDAMENTALS RATINGS
NVS vs NVSEF: Fundamental Ratings
NVS
NVSEF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
1124
SMR RATING
1..100
2929
PRICE GROWTH RATING
1..100
4646
P/E GROWTH RATING
1..100
7878
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (15) in the Pharmaceuticals Major industry is in the same range as NVSEF (16) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVS's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as NVSEF (24) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as NVSEF (29) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as NVSEF (46) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

NVS's P/E Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as NVSEF (78) in the null industry. This means that NVS’s stock grew similarly to NVSEF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSNVSEF
RSI
ODDS (%)
Bearish Trend 4 days ago
38%
Bearish Trend 4 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
37%
Bearish Trend 4 days ago
43%
Momentum
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 4 days ago
53%
MACD
ODDS (%)
Bullish Trend 4 days ago
52%
Bullish Trend 4 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 4 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
46%
Bullish Trend 4 days ago
49%
Advances
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 19 days ago
50%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
32%
Bearish Trend 4 days ago
61%
Aroon
ODDS (%)
Bullish Trend 4 days ago
41%
Bullish Trend 4 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMOS17.500.45
+2.64%
ChipMOS TECHNOLOGIES
TLK19.420.18
+0.94%
PT Telekomunikasi Indonesia
TDW57.730.53
+0.93%
Tidewater
BSBK9.40-0.04
-0.48%
Bogota Financial Corp
HCWB4.24-0.39
-8.42%
HCW Biologics Inc

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.02%
GSK - NVS
68%
Closely correlated
+2.25%
AZN - NVS
61%
Loosely correlated
-0.10%
PFE - NVS
57%
Loosely correlated
+1.39%
JNJ - NVS
54%
Loosely correlated
-0.18%
SNY - NVS
54%
Loosely correlated
+2.58%
More

NVSEF and

Correlation & Price change

A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVSEF
1D Price
Change %
NVSEF100%
N/A
SNYNF - NVSEF
27%
Poorly correlated
+0.54%
SNY - NVSEF
21%
Poorly correlated
+2.58%
NVS - NVSEF
20%
Poorly correlated
+1.02%
KYKOF - NVSEF
7%
Poorly correlated
N/A
GIKLY - NVSEF
6%
Poorly correlated
N/A
More